DexCom (NASDAQ:DXCM) EVP Sells $145,316.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total transaction of $145,316.00. Following the completion of the transaction, the executive vice president owned 98,185 shares of the company’s stock, valued at approximately $8,392,853.80. This trade represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Tuesday, September 15th, Michael Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $84.04, for a total transaction of $142,868.00.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $80.26 on Thursday. The firm has a market cap of $30.29 billion, a PE ratio of 31.72, a price-to-earnings-growth ratio of 1.44 and a beta of 1.48. The firm’s fifty day moving average is $87.29 and its 200-day moving average is $76.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.48 earnings per share. Sell-side analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Truist Financial set a $102.00 price target on DexCom and gave the company a “buy” rating in a research report on Friday, September 18th. Wells Fargo & Company raised their price objective on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Barclays raised DexCom to a “strong-buy” rating in a research note on Wednesday, October 7th. Benchmark upped their target price on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $105.00 target price (up from $90.00) on shares of DexCom in a research report on Thursday, October 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of “Buy” and an average price target of $92.43.

Institutional Investors Weigh In On DexCom

Several large investors have recently added to or reduced their stakes in DXCM. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in DexCom by 15.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after buying an additional 1,515,702 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of DexCom by 32.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock worth $166,077,000 after buying an additional 645,534 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of DexCom during the 2nd quarter worth approximately $173,237,000. Arrowstreet Capital Limited Partnership grew its position in shares of DexCom by 100.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock worth $159,832,000 after buying an additional 1,275,142 shares during the period. Finally, Deutsche Bank AG bought a new stake in shares of DexCom in the 2nd quarter valued at $164,035,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.